Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Amezalpat · TPST-1120

Small molecule · Antagonist of peroxisome proliferator-activated receptor alpha (PPARA) · developed by Tempest Therapeutics

Phase 1/2 Most advanced trial
1 Registered trials

What is Amezalpat?

Amezalpat is an orally bioavailable small molecule antagonist of PPARα that blocks fatty acid oxidation in tumor cells and the tumor microenvironment. By shifting metabolism toward glycolysis and reducing immunosuppressive cell populations, it enhances anti-tumor immune responses. It is being studied in advanced liver cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TPST-1120
Drug type
Small molecule
Targets
peroxisome proliferator-activated receptor alpha (PPARA)
Mechanism
Antagonist of peroxisome proliferator-activated receptor alpha (PPARA)
Pathways
fatty acid oxidation, glycolysis, angiogenesis, interferon signaling
Therapy area
Oncology
Developer
Tempest Therapeutics
In trials of
ADAG
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
1EQ4LQN9N3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04524871 Phase 1/2 Advanced Liver Cancers Active not recruiting ADAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Liver Cancers

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.